제제 개발 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 제제별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Formulation Development Outsourcing Market Growth & Trends:

The global formulation development outsourcing market size is estimated to reach USD 60.66 billion by 2030, registering a CAGR of 8.62% from 2025 to 2030, according to a new report by Grand View Research, Inc. The high burden of chronic and infectious diseases, the growing focus on improving the bioavailability of poorly soluble drugs, and the complications associated with drug development are contributing to the demand for formulation development services globally. Furthermore, the COVID-19 outbreak has influenced the need for clinical trials to find an effective treatment against the contagious virus. This has resulted in significant investments in research and development (R&D) to develop therapeutics, which are expected to drive the market.

According to Pharma R&D Annual Review 2022, biopharmaceutical and anticancer drugs are the major drugs in the development stage in the year 2022, this is expected to improve the demand for formulation development of these drugs post-pandemic. Globally, the pharmaceutical companies are making significant contributions to R&D activities. For instance, Merck's R&D cost was USD 2,516.8 million in 2020 as compared to USD 2,494.8 million in 2019. Similarly, Biogen's R&D expenses accounted for USD 3,990.9 million in 2020. The company's R&D expenditure increased by 75% as compared to 2019. The significant increase in R&D expenditure is likely to have a positive impact on the market.

A significant number of drugs fail to reach late-stage clinical trials owing to complications associated with formulation development. Moreover, strict regulations regarding the development of drugs are further contributing to the demand for outsourcing formulation development. Such factors are expected to improve the demand. The COVID-19 incidence has been significantly reduced owing to the growing vaccination drive globally. As a result, the CRO and CDMO are once again concentrating on the development of drugs for oncology and other disorders. For instance, in April 2022, Labcorp collaborated with Xcell Biosciences to support the company in developing cell and gene therapies for treating cancer, Parkinson's disease, and other rare diseases. Such initiatives by the CDMOs are likely to promote the demand for the formulation development outsourcing of drugs used in the treatment of cancer and other rare diseases.

Formulation Development Outsourcing Market Report Highlights:

• Based on services, the preformulation segment is expected to grow at the fastest CAGR during the forecast period.
• Based on formulation, the drug product segment is expected to grow at a significant CAGR during the forecast period.
• Based on therapeutic area, the oncology segment accounted for the largest market revenue share in 2024.
• Asia Pacific held the largest revenue share in 2024, due to the presence of a significant number of CROs providing cost effective formulation development services.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Formulation
  • 1.2.3. Therapeutic Area
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Formulation Development Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Clinical Trials Volume Analysis, (2024)
  • 3.3.1. Total Number of Clinical Trials By Region
  • 3.3.2. Total Number of Clinical Trials, By Phase
  • 3.3.3. Total Number of Clinical Trials, By Study Design
  • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
• 3.4. Pricing Model Analysis
• 3.5. Technology Landscape
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Formulation Development Outsourcing Market: Service Estimates & Trend Analysis

• 4.1. Formulation Development Outsourcing Market, By Service: Segment Dashboard
• 4.2. Formulation Development Outsourcing Market, By Service: Movement Analysis
• 4.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Service, 2018 - 2030
• 4.4. Preformulation
  • 4.4.1. Preformulation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Formulation Development
  • 4.5.1. Formulation Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Formulation Development Outsourcing Market: Formulation Estimates & Trend Analysis

• 5.1. Formulation Development Outsourcing Market, By Formulation: Segment Dashboard
• 5.2. Formulation Development Outsourcing Market, By Formulation: Movement Analysis
• 5.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Formulation, 2018 - 2030
• 5.4. Oral
  • 5.4.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Injectable
  • 5.5.1. Injectable Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Topical
  • 5.6.1. Topical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Formulation Development Outsourcing Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Formulation Development Outsourcing Market, By Therapeutic Area: Segment Dashboard
• 6.2. Formulation Development Outsourcing Market, By Therapeutic Area: Movement Analysis
• 6.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Infectious Disease
  • 6.5.1. Infectious Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Neurology
  • 6.6.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Hematology
  • 6.7.1. Hematology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Respiratory
  • 6.8.1. Respiratory Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Cardiovascular
  • 6.9.1. Cardiovascular Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Dermatology
  • 6.10.1. Dermatology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Formulation Development Outsourcing Market: End Use Estimates & Trend Analysis

• 7.1. Formulation Development Outsourcing Market, By End Use: Segment Dashboard
• 7.2. Formulation Development Outsourcing Market, By End Use: Movement Analysis
• 7.3. Formulation Development Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
• 7.4. Pharmaceutical and Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Government and Academic Institutes
  • 7.5.1. Government and Academic Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Formulation Development Outsourcing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Netherlands
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Netherlands Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Switzerland
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.10. Denmark
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.11. Norway
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. Japan
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Indonesia
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.8. Malaysia
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.9. Singapore
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.10. Thailand
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Framework
    • 8.6.10.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.11. Taiwan
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Framework
    • 8.6.11.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. Colombia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Chile
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Egypt
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.6. Israel
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Framework
    • 8.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.7. Kuwait
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Competitive Scenario
    • 8.8.7.3. Regulatory Framework
    • 8.8.7.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Share/Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. SGS S.A.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Intertek Group plc
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Recipharm
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Lonza
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Charles River Laboratories International, Inc.
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Eurofins Scientific SE
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Element
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Labcorp
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Thermo Fisher Scientific, Inc.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Catalent Inc.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives

Chapter 10. Key Recommendations